Enhanced GPCR Heteromer Inhibitors and Methods for Cancer Treatment

This inventive concept presents novel improvements to GPCR heteromer inhibitors, enhancing their bioavailability, reducing side effects, and improving cancer treatment outcomes through combination therapies and advanced diagnostic tools.

The original patent disclosed GPCR heteromer inhibitors for cancer treatment, but had limitations in terms of bioavailability, side effects, and efficacy. This inventive concept addresses these limitations by introducing novel formulations, combination therapies, and diagnostic tools to improve treatment outcomes.

The new inventive concept comprises four main aspects: 1) a method for treating CXCR4-related cancer using a CXCR4-HRH1 heteromer inhibitor and a CXCL12-neutralizing antibody, formulated to enhance bioavailability and reduce side effects; 2) a system for identifying CXCR4-HRH1 heteromer-specific inhibitors using a high-throughput screening platform and machine learning algorithm; 3) a composition of matter comprising a CXCR4-HRH1 heteromer inhibitor and a chemerin receptor agonist, which reduces cancer cell proliferation and enhances anti-tumor immune responses; and 4) a method for diagnosing CXCR4-related cancer using a multiplex immunofluorescence assay and correlating expression levels with disease prognosis and treatment response. These aspects work together to provide a comprehensive approach to cancer treatment.

The new inventive concept introduces novel formulations, combination therapies, and diagnostic tools that overcome the limitations of the original patent. The use of machine learning algorithms and high-throughput screening platforms for identifying inhibitors, as well as the combination of CXCR4-HRH1 heteromer inhibitors with chemerin receptor agonists, represents a significant inventive step beyond the original patent.

Alternative embodiments of the inventive concept could include the use of different GPCR heteromers, alternative formulations for improved bioavailability, or the integration of additional diagnostic tools, such as liquid biopsies or genomic analysis. Variations of the composition of matter could include different ratios of CXCR4-HRH1 heteromer inhibitors to chemerin receptor agonists or the addition of other therapeutic agents.

The inventive concept has significant commercial potential in the cancer treatment market, particularly in the areas of CXCR4-related cancers. The development of novel formulations, combination therapies, and diagnostic tools could provide a competitive advantage in the market and improve treatment outcomes for patients.